60 Vegi-Caps
AOR04208
100%
Vegetarian
SUPPLEMENT FACTS
Serving Size: 2 Capsules
| Zinc Carnosine
|
75
mg
|
|
Mixed Tocopherols
|
400 mg
|
| Mixed Tocotrienols
|
202 mcg
|
Non-medicinal ingredients: Capsule; hypromellose, gellan
gum, potassium acetate, water.
AOR™ guarantees that no ingredients
not listed on the label have been added to the product. Contains no
wheat, gluten, corn, nuts, dairy, eggs, fish or shellfish.
Suggested
use
Take 2 capsules daily with food, or as directed by a
qualified health care practitioner.
Main Applications
Leaky gut
Gastric and
duodenal ulcers
Helicobacter Pylori infection
Autism
Source
Tocopherols – soy bean
Tocotrienols –
palm fruit
Pregnancy/Nursing
Do not take if pregnant or
nursing
Cautions
None known
*These statements
have not been evaluated by the Food and Drug Administration. This
product is not intended to diagnose, treat, cure, or prevent any
disease.
Zinc and Carnosine – A
Protective Combination
Zinc-Carnosine is a chelated
Zinc-Carnosine complex that has been a successful pharmaceutical drug in
Japan since 1994 for the treatment of stomach disorders such as ulcers,
dyspepsia and infections with Helicobacter pylori, the bacteria
associated with stomach ulcers. Clinical trials have demonstrated
remarkable improvements in symptoms including heartburn, nausea,
vomiting, belching, bloating and anorexia and improved healing rates
during supplementation with Zinc-Carnosine.
In a 1992, double-blind multicentre
Japanese human study, the Zinc-Carnosine treatment group showed
"moderate improvement or better" of symptoms reaching 81.0 % after 4
weeks and 91.7% after 8 weeks. The ulcer cure rate for the
Zinc-Carnosine group was 26.3% after 4 weeks and 60.4% after 8 weeks.
There were no drug reactions or adverse drug events. In another human
study, a dose of 75mg twice a day showed gastric healing rates of 40%
after 4 weeks and over 70% after 8 weeks.
With dozens of research studies and over
12 years of human experience as a prescription product, Zinc-Carnosine
has a strong track record of safety, efficacy and scientific merit and
is a natural medicine of choice for all sorts of gastrointestinal
problems. Zinc-Carnosine can be especially helpful for individuals with
“leaky gut syndrome”, a condition associated with increased gut
permeability. This condition is associated with many chronic diseases
ranging from auto-immune diseases like IBD and MS to autism. Symptoms of
a leaky gut are varied and include abdominal pain, constipation,
bloating, malnutrition, memory loss, fatigue, infections, reduced
immunity, memory loss and many others.
Zinc-carnosine has been shown to
stabilize the gut mucosa and to stimulate healing and repair in the GI
tract. In humans, zinc-carnosine has also been shown to protect the gut
from damage caused by non-steroidal anti-inflammatory drugs. In a study
of 10 volunteers aged 24-40, zinc carnosine prevented increases in gut
permeability (an indication of intestinal damage) after participants
took indomethacin, a non-steroidal anti-inflammatory drug known to cause
gastrointestinal damage. Indomethacine caused a threefold increase in
gut permeability in the control group, but there was no significant
change in permeability when zinc carnosine was also administered.
Vitamin E Complex
Vitamin E is a powerful antioxidant, and
can therefore help to reduce oxidative stress in the gastrointestinal
tract and throughout the body. Many chronic conditions have been linked
to increased oxidative stress, which can be mediated by antioxidants
like a complete vitamin E complex. Vitamin E also helps to maintain the
integrity of cell membranes and has protective effects in the
gastrointestinal tract. For example, alpha-tocopherol has been found to
dose-dependently suppress the formation of gastric ulcers and the
activation of certain immune cells, which may help decrease
inappropriate inflammation.
Support for Autistic Spectrum
Disorders
Autistic disorders are pervasive
developmental disorders that occur in as many as 1 out of 250 children.
Children with autism generally begin to manifest symptoms of abnormal
social interaction and communication in the first three years of life.
Autism is created by a dysfunction in the central nervous system. The
cause of this disorder is very unclear and currently there is no cure,
although there are several treatments that have been brought forward as
having the potential to relieve symptoms.
Many studies have suggested a link
between autistic symptoms and gastrointestinal defects. Clinical
assessments of gastrointestinal symptoms have suggested that up to half
of autistic children have gastrointestinal abnormalities. Increasing
evidence suggests a link between autistic disorder and oxidative stress,
where cells are damaged by free radicals. Increased oxidative stress
can lead to damaged membrane lipids and to abnormalities in the immune
and inflammatory systems, which could in turn contribute to the
behavioral problems and gastrointestinal abnormalities commonly found in
autism.
Aside from helping to reduce the
gastrointestinal problems associated with autism, Zinc-Carno E can also
have benefits for behavior and cognition. Preliminary trials have found
behavioral improvements in autistic individuals who are supplemented
with antioxidants like vitamin E and carnosine. For example, one study
found that autistic children supplemented with carnosine showed
significant improvements in receptive speech, socialization and
behavior. In another study, children who were given carnosine had a
reduced frequency of seizures, as well as improvements in
electroencephalogram findings, which measure brain wave activity. Still
more, the children were found to have improvements in overall cognition,
behavior, and language function.
References
Jpn Pharmacol Ther 1992; 20;
199-223. Clinical evaluation of Z-103 on Gastric Ulcer, A multicenter
Double-Blind Study with Cetraxate Hydrocholride.
Jpn
Pharmacol Ther 1992; 20 (1). Clinical Evaluation of Z-103 on Gastric
Ulcer - Results of phase III general clinical trial.
Chez MG, Buchanan CP, Aimonovitch
MC, Becker M, Shaefer K, Black C and Komen J. Double-blind,
placebo-controlled study of L-carnosine supplementation in children with
autistic spectrum disorders. J Child Neurol 2002;17:833-837.
Mahmood A, FitzGerald AJ, Marchbank
T, Ntatsaki E, Murray D, Ghosh S and Playford RJ. Zinc carnosine, a
health food supplement that stabilizes small bowel integrity and
stimulates gut repair processes. Gut 2007;56:168-175.
Horvath K, Perman JA. Autistic
disorder and gastrointestinal disease. Curr Opin Pediatr.
2002;14(5):583-7.
Double-blind, placebo-controlled study of
L-carnosine supplementation in children with autistic spectrum
disorders.
Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Shaefer K, Black
C and Komen J. J Child Neurol 2002;17:833-837.
L-Carnosine,
a dipeptide, can enhance frontal lobe function or be neuroprotective.
It can also correlate with gamma-aminobutyric acid (GABA)-homocarnosine
interaction, with possible anticonvulsive effects. We investigated 31
children with autistic spectrum disorders in an 8-week, double-blinded
study to determine if 800 mg L-carnosine daily would result in
observable changes versus placebo. Outcome measures were the Childhood
Autism Rating Scale, the Gilliam Autism Rating Scale, the Expressive and
Receptive One-Word Picture Vocabulary tests, and Clinical Global
Impressions of Change. Children on placebo did not show statistically
significant changes. After 8 weeks on L-carnosine, children showed
statistically significant improvements on the Gilliam Autism Rating
Scale (total score and the Behavior, Socialization, and Communication
subscales) and the Receptive One-Word Picture Vocabulary test (all P
< .05). Improved trends were noted on other outcome measures.
Although the mechanism of action of L-carnosine is not well understood,
it may enhance neurologic function, perhaps in the enterorhinal or
temporal cortex.
Zinc carnosine, a health food supplement that stabilizes small
bowel integrity and stimulates gut repair processes.
Mahmood A, FitzGerald AJ, Marchbank T, Ntatsaki E, Murray D,
Ghosh S and Playford RJ. Gut 2007;56:168-175.
BACKGROUND:
Zinc carnosine (ZnC) is a health food product claimed to possess
health-promoting and gastrointestinal supportive activity. Scientific
evidence underlying these claims is, however, limited. AIM: To examine
the effect of ZnC on various models of gut injury and repair, and in a
clinical trial. METHODS: In vitro studies used pro-migratory (wounded
monolayer) and proliferation ([(3)H]-thymidine incorporation) assays of
human colonic (HT29), rat intestinal epithelial (RIE) and canine kidney
(MDCK) epithelial cells. In vivo studies used a rat model of gastric
damage (indomethacin/restraint) and a mouse model of small-intestinal
(indomethacin) damage. Healthy volunteers (n = 10) undertook a
randomised crossover trial comparing changes in gut permeability
(lactulose:rhamnose ratios) before and after 5 days of indomethacin
treatment (50 mg three times a day) with ZnC (37.5 mg twice daily) or
placebo coadministration. RESULTS: ZnC stimulated migration and
proliferation of cells in a dose-dependent manner (maximum effects in
both assays at 100 micromol/l using HT29 cells), causing an approximate
threefold increase in migration and proliferation (both p<0.01). Oral
ZnC decreased gastric (75% reduction at 5 mg/ml) and small-intestinal
injury (50% reduction in villus shortening at 40 mg/ml; both p<0.01).
In volunteers, indomethacin caused a threefold increase in gut
permeability in the control arm; lactulose:rhamnose ratios were (mean
(standard error of mean)) 0.35 (0.035) before indomethacin treatment and
0.88 (0.11) after 5 days of indomethacin treatment (p<0.01), whereas
no significant increase in permeability was seen when ZnC was
coadministered. CONCLUSION: ZnC, at concentrations likely to be found in
the gut lumen, stabilises gut mucosa. Further studies are warranted.